Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,577 Million (Mid Cap)
33.00
NA
0.37%
-0.58
6.45%
2.15
Revenue and Profits:
Net Sales:
537 Million
(Quarterly Results - Jun 2025)
Net Profit:
45 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.99%
0%
5.99%
6 Months
-3.17%
0%
-3.17%
1 Year
5.2%
0%
5.2%
2 Years
-4.18%
0%
-4.18%
3 Years
-54.47%
0%
-54.47%
4 Years
-51.68%
0%
-51.68%
5 Years
0%
0%
0.0%
Novogene Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.98%
EBIT Growth (5y)
-0.99%
EBIT to Interest (avg)
78.60
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.58
Sales to Capital Employed (avg)
0.86
Tax Ratio
8.59%
Dividend Payout Ratio
10.40%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
15.78%
ROE (avg)
9.34%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
2.42
EV to EBIT
27.08
EV to EBITDA
13.93
EV to Capital Employed
4.47
EV to Sales
2.19
PEG Ratio
NA
Dividend Yield
0.33%
ROCE (Latest)
16.52%
ROE (Latest)
7.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
536.80
527.20
1.82%
Operating Profit (PBDIT) excl Other Income
80.80
91.00
-11.21%
Interest
0.40
0.30
33.33%
Exceptional Items
1.20
1.30
-7.69%
Consolidate Net Profit
45.40
53.40
-14.98%
Operating Profit Margin (Excl OI)
73.40%
95.80%
-2.24%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 1.82% vs 7.99% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -14.98% vs -1.48% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,106.50
1,997.50
5.46%
Operating Profit (PBDIT) excl Other Income
358.60
328.20
9.26%
Interest
2.90
3.50
-17.14%
Exceptional Items
5.10
-2.30
321.74%
Consolidate Net Profit
203.80
183.20
11.24%
Operating Profit Margin (Excl OI)
93.00%
88.00%
0.50%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5.46% vs 4.07% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 11.24% vs 0.94% in Dec 2023
About Novogene Co., Ltd. 
Novogene Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






